We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In observance of the Thanksgiving holiday, Drug Industry Daily will not be published Thursday, Nov. 28, or Friday, Nov. 29. The next issue will be published Monday, Dec. 2. Read More
Federal prosecutors have opened a criminal investigation into whether pharmaceutical companies violated the federal Controlled Substances Act (CSA), which is usually used to prosecute drug dealers. Read More
FDA Principal Deputy Commissioner Amy Abernethy announced on Tuesday that the agency will clarify its regulatory approach to cannabidiol products in light of the increasing illegal marketing of CBD products as FDA approved.
Read More
The FDA’s Office of Prescription Drug Promotion sent an untitled letter to Rockwell Medical of Wixom, Michigan over its web page for Triferic (ferric pyrophosphate citrate), an iron-replacement for adults with hemodialysis-dependent chronic kidney disease.
Read More
Novartis has forged a merger agreement with The Medicines Company under which it will buy up the firm’s cholesterol drug inclisiran for a whopping $9.7 billion. Read More
The FDA hit Florida stem-cell supplier RichSource Stem Cells with an untitled letter for unapproved claims relating to its RICHGEN stem cell product.
Read More